Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.34 is 187% above its 5-year average of 0.12, near the high end of its 5-year range (-1.55–0.34).
As of the fiscal period ended Tuesday, June 30, 2026. 62.77% above its 12-month average of 0.21.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.34.
DEBT TO EQUITY RATIO
0.34
DEBT TO EQUITY RATIO AVG TTM
0.21
DEBT TO EQUITY RATIO AVG 3Y
0.18
DEBT TO EQUITY RATIO AVG 5Y
0.12
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+62.77%
CURRENT VS 3Y AVG
+90.82%
CURRENT VS 5Y AVG
+187.13%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 516 covered companies
CURRENT VS SECTOR MEDIAN
+154.77%
vs the sector median at left
Alpha Tau Medical Ltd
Market Cap
$1.31B
Debt to Equity Ratio
0.34
TTM Avg
0.21
3Y Avg
0.18
5Y Avg
0.12
Market Cap
$1.32B
Debt to Equity Ratio
0.00
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.33B
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$1.34B
Debt to Equity Ratio
0.01
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.38B
Debt to Equity Ratio
N/A
TTM Avg
6.73
3Y Avg
5.46
5Y Avg
3.96
Market Cap
$1.21B
Debt to Equity Ratio
0.37
TTM Avg
0.40
3Y Avg
0.41
5Y Avg
0.36
Market Cap
$1.19B
Debt to Equity Ratio
N/A
TTM Avg
0.97
3Y Avg
0.56
5Y Avg
0.37
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alpha Tau Medical Ltd (DRTS) | $1.31B | 0.34 | 0.21 | 0.18 | 0.12 |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.32B | 0.00 | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | 0.00 | 0.00 | 0.00 | 0.00 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.34B | 0.01 | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.38B | N/A | 6.73 | 5.46 | 3.96 |
| Innovage Holding Corp. (INNV)vs › | $1.21B | 0.37 | 0.40 | 0.41 | 0.36 |
| AnaptysBio, Inc. (ANAB)vs › | $1.41B | 25.47 | 2.79 | 1.47 | 0.99 |
| Cronos Group Inc. (CRON)vs › | $1.21B | 0.00 | 0.00 | 0.00 | 0.00 |
| MannKind Corporation (MNKD)vs › | $1.19B | N/A | 0.97 | 0.56 | 0.37 |
| Kardigan, Inc. (KARD)vs › | $1.15B | 0.02 | N/A | N/A | N/A |
Debt/Equity
0.34
Current Ratio
11.09
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.34 |
| 2026-03-31 | 0.21 |
| 2025-12-31 | 0.18 |
| 2025-09-30 | 0.17 |
| 2025-06-30 | 0.15 |
| 2025-03-31 | 0.22 |
| 2024-12-31 | 0.20 |
| 2024-09-30 | 0.18 |
| 2024-06-30 | 0.17 |
| 2024-03-31 | 0.16 |
| 2023-12-31 | 0.16 |
| 2023-09-30 | 0.07 |
| 2023-06-30 | 0.07 |
| 2023-03-31 | 0.06 |
| 2022-12-31 | 0.05 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | -1.55 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | -6.40 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.00 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
